Cover Image
市場調查報告書

發炎性腸道疾病(IBD):全球治療藥產業及市場

Inflammatory Bowel Diseases (IBD) 2016-2026: Revenue Forecasts and R&D for Aminosalicylates, Antibiotics, Corticosteroids, Biologics and Immunomodulators Treating Disorders Including Crohn's Disease and Ulcerative Colitis

出版商 Visiongain Ltd 商品編碼 209072
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
發炎性腸道疾病(IBD):全球治療藥產業及市場 Inflammatory Bowel Diseases (IBD) 2016-2026: Revenue Forecasts and R&D for Aminosalicylates, Antibiotics, Corticosteroids, Biologics and Immunomodulators Treating Disorders Including Crohn's Disease and Ulcerative Colitis
出版日期: 2016年01月18日 內容資訊: 英文 190 Pages
簡介

本報告提供全球發炎性腸道疾病市場現狀與未來發展預測相關分析、收益預測、成長率、市場佔有率、SWOT分析、各地區趨勢等彙整資料,以及專家的見解,為您概述為以下內容。

第1章 調查概要

第2章 發炎性腸道疾病市場簡介

  • 發炎性腸道疾病(IBD)為何?
  • IBD的分類
  • IBD的徵兆及診斷
  • IBD有多普遍?
  • IBD的治療選擇為何?
  • IBD的治療目標:針對目標達成的治療的方法
  • 治療流程:今後的方向性是Top-Down(由上而下)型方法嗎?

第3章 全球IBD市場

  • IBD市場
  • 預測:生技仿製藥的影響為何?
  • 生物學的療法的預測
  • 胺基水楊酸的德預測
  • 抗生素的預測
  • 皮質類固醇的預測
  • 免疫調節藥的預測

第4章 主要IBD治療藥的市場展望

  • Humira (AbbVie)
  • Remicade (Janssen Biotech)
  • Asacol (Actavis)
  • Pentasa (Shire)
  • Lialda (Shire)
  • Tysabri (Perrigo)
  • Xifaxan (Valeant)
  • Cimzia (UCB)
  • Entocort (AstraZeneca)
  • Neoral (Novartis)
  • Medrol (Pfizer)
  • Canasa (Allergan)
  • Apriso (Valeant) - Asacol的挑戰?
  • Azulfidine (Pfizer)
  • Entyvio (武田藥品工業)
  • Simponi (Janssen Biotech)
  • Uceris (Valeant)

第5章 主要國家市場:銷售額的展望

  • IBD治療藥:主要國家市場
  • 美國的IBD治療藥市場:全球領導者
  • 日本的IBD治療藥市場:大幅度擴大
  • EU主要5個國家的IBD治療藥市場:英國牽引
  • 金磚四國的IBD治療藥市場:市場佔有率更擴大

第6章 IBD的研發產品線

  • 白細胞介素(IL)抑制劑
  • 細胞黏合分子(CAM)抑制劑
  • TNF抑制劑
  • 幹細胞治療:治療的基本
  • JAK抑制劑:新的標的途徑
  • Tor容受體激動劑
  • 其他代理商級
  • 生技仿製藥候補藥:主要生技藥品的有前途的複製

第7章 IBD治療藥產業、市場促進因素與阻礙因素

  • IBD市場SWOT、STEP分析
  • IBD市場促進要素為何?
  • 市場阻礙要素為何?

第8章 IBD市場主要企業

  • 最大企業:各收益
    • AbbVie:目前領導者持續性地擴大
    • Janssen Biotech :未來市場領導者候補
    • Allergan:前四大企業中的新人
    • Shire Pharmaceuticals :預測

第9章 調查採訪

第10章 結論

  • IBD市場擴大預測
  • 胺基水楊酸以及其他非生物學的治療
  • 生物學的治療
  • IBD治療的改善的必要性
  • 未來的IBD治療:R&D的配合措施看來有希望
  • IBD部門:未來有穩定展望

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0085

Inflammatory Bowel Diseases - Your New Guide to Pharma R&D, Opportunities and Revenue Predictions

What does the future hold for drugs treating inflammatory bowel diseases (IBD)? Those intestinal medicines retain high potential. Now you can explore sales forecasts and that industry's research and development.

Visiongain's new report predicts those revenues to 2026 at overall world market, submarket, product and national level. There you assess commercial opportunities for therapies treating disorders including Crohn's disease and ulcerative colitis.

So please read on to examine those colonic treatments, seeing how high that industry's sales can go. Discover what is possible for that large, expanding market.

Forecasts and other analyses to help your gastrointestinal (GI) drug research, knowledge and influence

Avoid struggles to find that business information. Instead see what is happening in treating those lower digestive tract disorders. Now you can make your research, analysis and decisions on the IBD drugs market quicker and easier.

Besides revenue forecasting to 2026, our new report shows you sales results, growth rates, market shares and discussions. There you gain 93 tables, 42 charts and two interviews with organisations . Stay ahead in knowledge to help your work on IBD.

Forecasting of the overall IBD market and five therapeutic segments

Our study predicts overall world revenue to 2026 for treating those intestinal disorders. There you also find individual revenue predictions for five submarkets at world level:

  • Biologics, including monoclonal antibodies (mAbs)
  • Aminosalicylates
  • Antibiotics
  • Corticosteroids
  • Immunomodulators.

Discover there how competition and technological advances shape that industry. Also benefit your reputation for commercial insight and see how you can gain. That way you find where the money lies in that progressing, expanding pharma market.

For those lower gut treatments our analyses also investigate leading brands' prospects.

Forecasts for 17 top products - discover sales potentials

How will leading drugs perform to 2026 at world level? Our study forecasts individual revenues of 17 leading medicines for those colonic disorders, including these agents:

  • Humira
  • Remicade
  • Asacol
  • Pentasa
  • Lialda
  • Tysabri

image1

You also gain sales predictions for these brands:

  • Cimzia
  • Entocort
  • Uceris
  • Simponi
  • Entyvio

Our study shows how high sales can go, to 2026, revealing medicines and years with highest predicted growth and revenues. Treating large-intestine disease holds much commercial potential. Explore what the future holds for treating inflamed bowel.

You also discover geographical revenue predictions.

image2

Healthcare in national markets - what outlooks for those pharmaceuticals?

Our report shows you individual revenue forecasting to 2026 for 11 countries:

  • US
  • Japan
  • Germany, France, UK, Spain and Italy (EU5)
  • Brazil, Russia, India and China (BRIC)

image3

There you find countries with highest IBD revenues, demand and potential sales. Investigate progress, needs and opportunities, seeing how you can gain.

And how do changes, challenges and technological advances affect that biopharma industry and market? Our new investigation explains.

R&D and other trends influencing those therapies and their producers

Our new analysis explains policies, issues and R&D shaping the IBD drugs industry and market. Assess the effects of these influences:

  • IBD diagnosis, incidence and prevalence - see prospects for rising sales
  • Monoclonal antibodies (mAbs) and biosimilars (follow-on protein products) - assess their potentials for changing that GI drugs market
  • Drug delivery systems - advances in supporting technology
  • Competition from generic drugs - see how they can erode that market
  • Economic pressures - budgetary limitations in healthcare and therapy costs.

In particular our study discusses research and development, including drug candidates in these classes:

  • Interleukin (IL) inhibitors
  • Cell-adhesion molecule (CAM) inhibitors
  • TNF-alpha inhibitors
  • Stem cell therapies
  • JAK inhibitors
  • Toll-like receptor agonists.

R&D for IBD holds high potential. Our study shows that pharma segment's progress and prospects. There you explore what stimulates and restrains that market. Avoid falling behind. Instead see what the future holds and how you can benefit.

Treatments for inflamed lower intestine - top companies and 2019 market value

Our report predicts the overall world market for those products will reach $9.3bn in 2019, with revenue growth from 2016. IBD medicines hold high potential for investments, technologies, medical advances and sales. See what is possible.

That work also explores activities, results and potentials of top companies, especially these firms:

  • AbbVie
  • Janssen Biotech
  • Allergan
  • Shire Pharmaceuticals.

With our new study you see how that market can develop and perform, benefiting your insight and authority. Discover how you can help your research, analysis and planning, also benefiting your influence.

Ways Inflammatory Bowel Diseases (IBD) 2016-2026 helps your work

Our new investigation helps your work in these eight main ways:

  • World market revenue to 2026 - discover that industry's overall sales potential
  • 5 product classes' revenues to 2026 - investigate categories at world level, finding the most lucrative and promising groups
  • 17 leading drugs' revenues to 2026 - find sales predictions for top therapies, seeing how they can compete and succeed
  • 11 national markets in the Americas, Europe and Asia, with revenue forecasts to 2026 - discover the best countries for sales expansion
  • Activities of established, rising and emerging companies - hear about firms' products, sales, capabilities, advances and outlooks
  • Research and development - investigate progress in that industry, exploring technological, clinical and commercial opportunities
  • Interviews with two authorities - discover other experts' views, helping you compete and stay ahead
  • Analysis of what stimulates and restrains the IBD drugs market - assess challenges, strengths and opportunities, helping you succeed.

That study gives original business analysis. There gain knowledge found only in the work of our in-house analysts in London, UK. Discover what the future holds.

Trying our study now lets you explore trends, opportunities and sales forecasts

Our new analysis shows you results, trends and opportunities. There you gain multilevel revenue predictions to 2026 for inflammatory bowel medicines, discovering the possible gains. Avoid missing out. Instead please get our report here now.

Table of Contents

1. Report Overview

  • 1.1 World IBD Drugs Market: Overview of Findings
  • 1.2 Why You Should Read This Report
  • 1.3 How the Study Delivers
  • 1.4 Main Questions Covered in the Analysis
  • 1.5 Who Is This Report For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Reports
  • 1.9 About Visiongain

2. Introduction to the Inflammatory Bowel Disease Drug Market

  • 2.1 What is Inflammatory Bowel Disease (IBD)?
  • 2.2 Classification of IBD
  • 2.3 Symptoms and Diagnosis of IBD
  • 2.4 Multifactorial Causes of IBD
  • 2.5 How Common is IBD?
  • 2.6 What Are the Treatment Options for IBD?
    • 2.6.1 Aminosalicylates - The Most Common therapy
    • 2.6.2 Antibiotics - Will There Be Any Supporting Evidence Soon?
    • 2.6.3 Corticosteroids - Uptake from Uceris?
    • 2.6.4 Immunomodulators - Slow to Act?
    • 2.6.5 Monoclonal Antibodies - Not cost-effective?
  • 2.7 Treatment Goals for IBD - Treat-to-Target Approach?
  • 2.8 Treatment Algorithm - is Top-Down Approach the Future Direction?

3. The World Inflammatory Bowel Disease Drug Market, 2016-2026

  • 3.1 The Inflammatory Bowel Disease Market in 2014 and 2015
  • 3.2 Forecast 2016-2026: Impacted by Biosimilars?
  • 3.3 Biologic Therapies Forecast 2016-2026 - Driving the Market
  • 3.4 Aminosalicylates Forecast 2016-2026: The Work Horse of IBD Market
  • 3.5 Antibiotics Forecast 2016-2026: Growing Despite Challenges
  • 3.6 Corticosteroids Forecast 2016-2026: Driven by Uceris
  • 3.7 Immunomodulators Forecast 2016-2026 - Will Slowly Lose Market Share

4. Market Prospects for Leading IBD Drugs, 2016-2026

  • 4.1 Humira (AbbVie) - Growing in the First Half of Forecast Period
    • 4.1.1 Humira: Forecast and Analysis, 2016-2026
  • 4.2 Remicade (Janssen Biotech) - Will Slowly be Eroded by Biosimilars
    • 4.2.1 Remicade: Forecast and Analysis, 2016-2026
  • 4.3 Asacol (Allergan) - Threat from Generic Competition
    • 4.3.1 Asacol: Forecast and Analysis, 2016-2026
  • 4.4 Pentasa (Shire) - Differentiated by Its Delivery System
    • 4.4.1 Pentasa: Forecast and Analysis, 2016-2026
  • 4.5 Lialda (Shire) - Will Improved Compliance Increase Revenue?
    • 4.5.1 Lialda: Forecast and Analysis, 2016-2026
  • 4.6 Tysabri (Perrigo) - Still Protected by Patent
    • 4.6.1 Tysabri: Forecast and Analysis, 2016-2026
  • 4.7 Xifaxan (Valeant) - Still Growing Significantly
    • 4.7.1 Xifaxan: Forecast and Analysis, 2016-2026
  • 4.8 Cimzia (UCB) - How Will it Fare Against Biosimilars?
    • 4.8.1 Cimzia: Forecast and Analysis, 2016-2026
  • 4.9 Entocort (AstraZeneca) - A Slow and Steady Decline?
    • 4.9.1 Entocort: Forecast and Analysis, 2016-2026
  • 4.10 Neoral (Novartis) - Will its Side Effect Profile Hamper Sales Growth?
    • 4.10.1 Neoral: Forecast and Analysis, 2016-2026
  • 4.11 Medrol (Pfizer) - Another Leading Steroid
    • 4.11.1 Medrol: Forecast and Analysis, 2016-2026
  • 4.12 Canasa (Allergan) - Will a Generic Competitor Soon Be Available?
    • 4.12.1 Canasa/Salofalk: Forecast and Analysis, 2016-2026
  • 4.13 Apriso (Valeant) - Challenger to Asacol?
    • 4.13.1 Apriso: Forecast and Analysis, 2016-2026
  • 4.14 Azulfidine (Pfizer) - Tried, Tested and Staying in the Market
    • 4.14.1 Azulfidine: Forecast and Analysis, 2016-2026
  • 4.15 Entyvio (Takeda Pharmaceuticals) - Driving the Biologics Segment
    • 4.15.1 Entyvio: Forecast and Analysis, 2016-2026
  • 4.16 Simponi (Janssen Biotech) - Rising Star for the Market?
    • 4.16.1 Simponi: Forecast and Analysis, 2016-2026
  • 4.17 Uceris (Valeant) - Meeting Patients' Needs with Its Delivery System
    • 4.17.1 Uceris: Forecast and Analysis, 2016-2026

5. Leading National Markets, 2016-2026

  • 5.1 IBD Drugs-Leading National Market 2014
  • 5.2 The US IBD Drug Market, 2016-2026 - The World Leader
  • 5.3 The Japanese IBD Drug Market, 2016-2026 - Growing Significantly?
  • 5.4 The EU-5 IBD Drug Market, 2016-2026 - Driven by the UK
    • 5.4.1 The German IBD Drug Market, 2016-2026
    • 5.4.2 The French IBD Drug Market, 2016-2026
    • 5.4.3 The UK IBD Drug Market, 2016-2026
    • 5.4.4 The Spanish IBD Drug Market, 2016-2026
    • 5.4.5 The Italian IBD Drug Market, 2016-2026
  • 5.5 IBD Drug Market in BRIC Countries - Taking More Market Share
    • 5.5.1 The Brazilian IBD Drug Market, 2016-2026
    • 5.5.2 The Russian IBD Drug Market, 2016-2026
    • 5.5.3 The Indian Drug Market, 2016-2026
    • 5.5.4 The Chinese IBD Drug Market, 2016-2026

6. The R&D Pipeline for Inflammatory Bowel Disease in 2015

  • 6.1 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation
    • 6.1.1 CyCol (Sigmoid Pharma Limited)
    • 6.1.2 PF-04236921 (Pfizer)
    • 6.1.3 QAX 576 (Novartis)
    • 6.1.4 TNF Kinoid (Neovacs)
    • 6.1.5 Vidofludimus (4SC) - Suspended
    • 6.1.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech, Inc.)
  • 6.2 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue
    • 6.2.1 AJG 511 (Ajinomoto Pharmaceutical Co., Ltd)
    • 6.2.2 AJM 300 (Ajinomoto Pharmaceuticals)
    • 6.2.3 MEDI 7183/AMG 181 (AstraZeneca & Amgen)
    • 6.2.4 Etrolizumab (Roche)
    • 6.2.5 PF-00547659 (Pfizer)
    • 6.2.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
    • 6.2.7 MEDI-2070/AMG 139 (AstraZeneca & Amgen)
  • 6.3 TNF-alpha Inhibitors - A Specific Target
    • 6.3.1 AVX-470 (Avaxia Biologics)
    • 6.3.2 Ozoralizumab (ALX-0061, Ablynx)
  • 6.4 Stem Cell Therapies - Basis for a Cure?
    • 6.4.1 Ovasave (TxCell)
    • 6.4.2 MultiStem (Athersys Inc and Pfizer)
    • 6.4.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
    • 6.4.4 Cx601 (TiGenix)
  • 6.5 JAK Inhibitors - New Target Pathway
    • 6.5.1 JNJ-54781532 (Janssen)
    • 6.5.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
  • 6.6 Toll-like Receptor Agonists - An Answer for Steroid-Refractory IBD?
    • 6.6.1 BL-7040 (BioLineRX)
    • 6.6.2 Kappaproct (InDex Pharmaceuticals)
  • 6.7 Other Classes of Agent
    • 6.7.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
    • 6.7.2 GLPG0974 (Galapagos)
    • 6.7.3 RPC1063 (Receptos/Celgene)
    • 6.7.4 SGX203 (Soligenix)
    • 6.7.5 Mongersen (GED-0301, Celgene)
    • 6.7.6 Tetomilast (OPC-6535, Otsuka)
    • 6.7.7 Laquinimod (Active Biotech)
    • 6.7.8 RHB-104 (RedHill Biopharma)
    • 6.7.9 Ozanimod (Celgene)
    • 6.7.10 GED-0301 (Celgene)
  • 6.8 Biosimilar Candidates - Promising Competitors of Leading Biologics
    • 6.8.1 Adalimumab Biosimilars
    • 6.8.2 Infliximab Biosimilars

7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2016

  • 7.1 SWOT and STEP Analyses of the IBD Drugs Market
  • 7.2 What Factors Will Drive the IBD Market?
    • 7.2.1 Increasing Disease Incidence in Most National Markets
    • 7.2.2 Better Diagnosis - Early Referrals
    • 7.2.3 Delivery Systems Improve Existing Drugs
    • 7.2.4 Biological Drugs - Driving the Market Significantly
    • 7.2.5 Socioeconomic Costs of IBD
  • 7.3 What Factors Will Restrain the Market?
    • 7.3.1 Lack of Understanding of Disease Aetiology
    • 7.3.2 Compliance - Frequent Dosing is Inconvenient
    • 7.3.3 Limits of Biologics - Side Effect Profiles
    • 7.3.4 The Possible Development of Alternative Treatments
    • 7.3.5 Surgery - Quality Depends on Time-Decision Making
    • 7.3.6 Health Care Cost Containment

8. Leading Companies in the IBD Pharmaceuticals Market

  • 8.1 The Largest Companies by Revenue
    • 8.1.1 AbbVie - Current Leader and Continually Expanding
    • 8.1.2 Janssen Biotech - Contender for Future Leader of the Market?
    • 8.1.3 Allergan- Newcomer to the Big Four
    • 8.1.4 Shire Pharmaceuticals - What is its Outlook?

9. Research Interviews

  • 9.1 Dr Didier Merlin, Institute for Biomedical Sciences, Georgia State University
    • 9.1.1 Unmet Needs in the Management of Ulcerative Colitis
    • 9.1.2 Curcumin for the Treatment of Ulcerative Colitis
    • 9.1.3 The Use of Curcumin in Clinical Settings - Limitations and Drawbacks
    • 9.1.4 Colitis-targeting Drug Release
    • 9.1.5 Potential Clinical Efficacy of this Novel Approach
  • 9.2 Dr Lawrence Kosinski, Founder and Chairman of SonarMD, LLC
    • 9.2.1 SonarMD, LLC
    • 9.2.2 SonarMD Platform - Patient Engagement Platform
    • 9.2.3 Differentiated from Other Patient Management Platforms
    • 9.2.4 Development Plans for Further Optimisation
    • 9.2.5 Parameters to Measure Impact in Clinical Settings
    • 9.2.6 SonarMD Platform - Raised Patient Acceptance Rate from 27% to 80%

10. Conclusions of the Study

  • 10.1 The IBD Drugs Market Will Expand from 2016 to 2026
  • 10.2 Aminosalicylates and Other Non-Biologic Treatments
  • 10.3 Biologic Treatments Dominate the Market
  • 10.4 Improvements Needed in IBD Therapy
  • 10.5 Future IBD Treatments: R&D Efforts Look Promising
  • 10.6 The IBD Sector: Looking to the Future with Confidence

List of Tables

  • Table 1.1 National IBD Drug Markets: Sizes ($m), Annual Growth (%), CAGR (%), 2015-2020
  • Table 1.2 National IBD Drug Markets: Sizes ($m), Annual Growth (%), CAGR (%), 2021-2026
  • Table 2.1 Differentiating Crohn's Disease and Ulcerative Colitis
  • Table 2.2 Worldwide Prevalence Rates for IBD, 2015
  • Table 2.3 Worldwide Incidence Rates for IBD, 2015
  • Table 2.4 Geographical Variations in the Incidence of IBD, 2015
  • Table 2.5 Other Drug Types Used to Treat IBD, 2015
  • Table 2.6 Treatment Protocol for IBD, 2015
  • Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2014 and 2015
  • Table 3.2 Global IBD Drug Market Forecast ($m), 2015-2026
  • Table 3.3 Global IBD Drug Forecasts by Drug Category ($m), 2015-2026
  • Table 3.4 Global IBD Drug Market Drivers and Restraints, 2016-2026
  • Table 3.5 Global Biologics Forecast for IBD Market ($m), 2015-2026
  • Table 3.6 Global Biologic Therapies Drivers and Restraints, 2016-2026
  • Table 3.7 Global Aminosalicylates Forecast for IBD Market ($m), 2015-2026
  • Table 3.8 Global Aminosalicylates Drivers and Restraints, 2016-2026
  • Table 3.9 Global Antibiotics Forecast for IBD Market ($m), 2015-2026
  • Table 3.10 Global Antibiotics Drivers and Restraints, 2016-2026
  • Table 3.11 Global Corticosteroids Forecast for IBD Market ($m), 2015-2026
  • Table 3.12 Global Corticosteroids Drivers and Restraints, 2016-2026
  • Table 3.13 Global Immunomodulators Forecast for IBD Market ($m), 2015-2026
  • Table 3.14 Global Immunomodulators Drivers and Restraints, 2016-2026
  • Table 4.1 Leading IBD Treatments by Revenue ($m), 2014
  • Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), 2015-2020
  • Table 4.3 Leading IBD Medicines: Revenue Forecasts ($m), 2021-2026
  • Table 4.4 World Humira Revenue Forecast ($m), 2015-2026
  • Table 4.5 Drivers and Restraints for Humira, 2016-2026
  • Table 4.6 World Remicade Forecast ($m), 2015-2026
  • Table 4.7 Drivers and Restraints for Remicade, 2016-2026
  • Table 4.8 World Asacol Forecast ($m), 2015-2026
  • Table 4.9 Drivers and Restraints for Asacol, 2016-2026
  • Table 4.10 World Pentasa Forecast ($m), 2015-2026
  • Table 4.11 Drivers and Restraints for Pentasa, 2016-2026
  • Table 4.12 World Lialda Forecast ($m), 2015-2026
  • Table 4.13 Drivers and Restraints for Lialda, 2016-2026
  • Table 4.14 World Tysabri Forecast ($m), 2015-2026
  • Table 4.15 Drivers and Restraints for Tysabri, 2016-2026
  • Table 4.16 World Xifaxan Forecast ($m), 2015-2026
  • Table 4.17 Drivers and Restraints for Xifaxan, 2016-2026
  • Table 4.18 World Cimzia Forecast ($m), 2015-2026
  • Table 4.19 Drivers and Restraints for Cimzia, 2016-2026
  • Table 4.20 World Entocort Forecast ($m), 2015-2026
  • Table 4.21 Drivers and Restraints for Entocort, 2016-2026
  • Table 4.22 World Neoral Forecast ($m), 2015-2026
  • Table 4.23 Drivers and Restraints for Neoral, 2016-2026
  • Table 4.24 World Medrol Forecast ($m), 2015-2026
  • Table 4.25 Drivers and Restraints for Medrol, 2016-2026
  • Table 4.26 World Canasa Forecast ($m), 2015-2026
  • Table 4.27 Drivers and Restraints for Canasa, 2016-2026
  • Table 4.28 World Apriso Forecast ($m), 2015-2026
  • Table 4.29 Drivers and Restraints for Apriso, 2016-2026
  • Table 4.30 World Azulfidine Forecast ($m), 2015-2026
  • Table 4.31 Drivers and Restraints for Azulfidine, 2016-2026
  • Table 4.32 World Entyvio Forecast ($m), 2015-2026
  • Table 4.33 Drivers and Restraints for Entyvio, 2016-2026
  • Table 4.34 World Simponi Forecast ($m), 2015-2026
  • Table 4.35 Drivers and Restraints for Simponi, 2016-2026
  • Table 4.36 World Uceris Forecast ($m), 2015-2026
  • Table 4.37 Drivers and Restraints for Uceris, 2016-2026
  • Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2014
  • Table 5.2 Global IBD Drug Market Forecasts by Leading Country ($m), 2015-2020
  • Table 5.3 Global IBD Drug Market Forecasts by Leading Country ($m), 2021-2026
  • Table 5.4 US IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.5 Japanese IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.6 EU5 IBD Drug Market Forecasts ($m), 2015-2020
  • Table 5.7 EU5 IBD Drug Market Forecasts ($m), 2021-2026
  • Table 5.8 German IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.9 French IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.10 UK IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.11 Spanish IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.12 Italian IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.13 BRIC IBD Drug Market Forecasts ($m), 2015-2020
  • Table 5.14 BRIC IBD Drug Market Forecasts ($m), 2021-2026
  • Table 5.15 Brazilian IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.16 Russian IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.17 Indian IBD Drug Market Forecast ($m), 2015-2026
  • Table 5.18 Chinese IBD Drug Market Forecast ($m), 2015-2026
  • Table 6.1 Selected IL Inhibitors in Clinical Development, 2015
  • Table 6.2 Selected CAM Inhibitors in Clinical Development, 2015
  • Table 6.3 Selected TNF-α Inhibitors in Clinical Development, 2015
  • Table 6.4 Selected Stem Cell Therapies in Clinical Development, 2015
  • Table 6.5 Selected JAK Inhibitors in Clinical Development, 2015
  • Table 6.6 Selected Toll-like Receptor Agonist in Clinical Development, 2015
  • Table 6.7 Selected Other Classes in Clinical Development, 2015
  • Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market, 2016
  • Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug Market, 2016
  • Table 8.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2014
  • Table 8.2 AbbVie Revenues ($m) and Market Share (%), 2014
  • Table 8.3 Janssen Biotech Revenues ($m) and Market Share (%), 2014
  • Table 8.4 Allergan Revenues ($m) and Market Share (%), 2014
  • Table 8.5 Shire Revenues ($m) and Market Share (%), 2014
  • Table 10.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Share (%) by Product Category, 2014, 2020, 2026
  • Table 10.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2014, 2020, 2026
  • Table 10.3 Summary of IBD Market Drivers and Restraints, 2016-2026

List of Figures

  • Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2016
  • Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2014
  • Figure 3.2 Global IBD Drug Market Forecast ($m), 2015-2026
  • Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2026
  • Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2015-2026
  • Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2015-2026
  • Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2015-2026
  • Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2015-2026
  • Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2015-2026
  • Figure 4.1 World Humira Revenue Forecast ($m), 2015-2026
  • Figure 4.2 World Remicade Forecast ($m), 2015-2026
  • Figure 4.3 World Asacol Forecast ($m), 2015-2026
  • Figure 4.4 World Pentasa Forecast ($m), 2015-2026
  • Figure 4.5 World Lialda Forecast ($m), 2015-2026
  • Figure 4.6 World Tysabri Forecast ($m), 2015-2026
  • Figure 4.7 World Xifaxan Forecast ($m), 2015-2026
  • Figure 4.8 World Cimzia Forecast ($m), 2015-2026
  • Figure 4.9 World Entocort Forecast ($m), 2015-2026
  • Figure 4.10 World Neoral Forecast ($m), 2015-2026
  • Figure 4.11 World Medrol Forecast ($m), 2015-2026
  • Figure 4.12 World Canasa Forecast ($m), 2015-2026
  • Figure 4.13 World Apriso Forecast ($m), 2015-2026
  • Figure 4.14 World Azulfidine Forecast ($m), 2015-2026
  • Figure 4.15 World Entyvio Forecast ($m), 2015-2026
  • Figure 4.16 World Simponi Forecast ($m), 2015-2026
  • Figure 4.17 World Uceris Forecast ($m), 2015-2026
  • Figure 5.1 Global IBD Drug Market by Leading Country (%), 2014
  • Figure 5.2 Global IBD Drug Market by Leading Country (%), 2026
  • Figure 5.3 US IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2015-2026
  • Figure 5.6 German IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.7 French IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.8 UK IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.10 Italian IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2015-2026
  • Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.13 Russian IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.14 Indian IBD Drug Market Forecast ($m), 2015-2026
  • Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2015-2026
  • Figure 8.1 Top Producers of IBD Drugs: Market Shares (%), 2014

Companies Listed

  • 4SC
  • Abbott Laboratories
  • AbbVie
  • Ablynx
  • Actavis
  • Active Biotech
  • Ajinomoto
  • Allergan
  • Almirall
  • Amgen
  • Aptalis Pharmaceuticals
  • Astellas
  • AstraZeneca
  • Athersys
  • Atlantic Healthcare
  • Avaxia Biologics
  • BioLineRx
  • Biosafe
  • Boehringer Ingelheim
  • Calico
  • Celgene
  • Celltrion
  • Center for Human Disease Research, Leiden
  • Centocor Ortho Biotech
  • Centrale Commissie Mensgebonden Onderzoek (CCMO)
  • Centres for Disease Control and Prevention (US)
  • Coherus Biosciences
  • Coronado Biosciences
  • Cosmo Pharmaceuticals
  • Crohn's and Colitis Foundation of Canada
  • Dr. Falk Pharma
  • Eddingpharm
  • Elan Pharmaceuticals
  • Epirus Biopharmaceuticals
  • European Medicines Agency (EMA)
  • Ferring
  • Food and Drug Administration (US FDA)
  • Forest Laboratories
  • Galapagos
  • Georgia State University
  • Giaconda
  • Google
  • Harbor Biosciences
  • Hebrew University of Jerusalem
  • Hospira
  • InDex Pharmaceuticals
  • Infinity Pharmaceuticals
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • IQWiG
  • Isis Pharmaceuticals
  • Janssen Biotech
  • Johnson & Johnson
  • Karolinska Institute
  • LG Sciences
  • MedImmune
  • Mochida
  • Mutare Health
  • Mylan Pharmaceuticals
  • National Health Service (UK NHS)
  • National Institute for Health and Care Excellence (UK NICE)
  • National Institutes of Health (US NIH)
  • Neovacs
  • Nisshin Kyorin
  • Nogra Pharma
  • Novartis
  • Oncobiologics
  • Ortho Biotech
  • Osiris Therapeutics
  • Otsuka
  • Ovamed
  • Palau Pharma
  • Pendopharm
  • Perrigo
  • Pfizer
  • Pharmascience
  • Pluristem Therapeutics
  • Quest Diagnostics
  • Ranbaxy Laboratories
  • Receptos
  • RedHill Biopharma
  • Reliance Life Sciences
  • Roche
  • Salix Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus
  • Sequella
  • Servicio Sanitario Nazionale (SSN, Italy)
  • Shire Pharmaceuticals
  • Sigmoid Pharma
  • Soligenix
  • SonarMD
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
  • The Crohn's and Colitis UK Foundation
  • The European Federation of Crohn's and Ulcerative Colitis Associations
  • TiGenix
  • Toray Industries
  • TxCell
  • UCB
  • Valeant
  • Warner Chilcott
  • Zydus Cadila
Back to Top